Qiagen N.V. announced it will publish fourth-quarter 2025 results on Wednesday, February 4, shortly after 22:05 Frankfurt time (21:05 London, 16:05 New York), followed by a conference call on Thursday, February 5 at 15:30 Frankfurt time (14:30 London, 09:30 New York). The call will feature CEO Thierry Bernard and CFO Peer Mühlhäuser discussing quarterly performance, including updates on Sample to Insight product revenues and margins. The company, which employs about 5,700 staff across 35+ locations and serves over 500,000 customers, will offer three access methods—call-back registration, direct dial-in, and an audio webcast—with replay available for 30 days via the event webcast portal. Bloomberg News reported that Qiagen’s board has initiated a strategic review to assess options, including a full sale of the diagnostics business, after receiving non-binding takeover approaches from multiple private equity firms and strategic buyers. Sources indicate that the company has engaged two global investment banks to advise on the process, and that preliminary indications of interest envisage a transaction valued in excess of $6 billion on an enterprise value basis. The review is expected to conclude in the first half of 2026, with the board weighing standalone development against potential merger or acquisition offers in light of robust end-market demand for molecular diagnostics.